Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1022 of 6351
-
New cell therapy trial offers hope for Hard-to-Treat myeloma
Disease control OngoingMaster protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.
Phase 1 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug cocktail shows promise in shrinking head and neck tumors before surgery
Disease control OngoingThe aim of this study is to potentiate adaptive immunity to enhance the anti-tumor activity of anti-PD1 antibody by the addition of anti-CTLA4 antibody or anti-LAG3 antibody (relatlimab) given in subjects with resectable locally advanced HNSCC prior to surgical resection.
Phase 2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Sep 09, 2026 23:00 UTC
-
New study tests which chemo combo works best for common breast cancers
Disease control OngoingThis study is a randomized, single center, phase III clinical trial comparing the efficacy and safety of four cycles of epirubicin combined with cyclophosphamide followed by four cycles of docetaxel (EC\*4-T\*4) verses 6 cycles of weekly paclitaxel combined with carboplatin (PCb\…
Phase 3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New combo therapy shows promise for advanced lung cancer patients
Disease control CompletedThe purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with MK-4830 in treatment-naïve participants with advanced squamous or non-squamous NSCLC that is PD-L1 positive. This study is one of three pembrolizumab substudies being co…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New asthma study aims to match treatments to patients
Disease control CompletedThe primary objective of this study is to evaluate several interventions given to participants with severe asthma. Interventions are administered in a crossover manner with 16-week treatment periods followed by 8 to 16 week washout.
Phase 2 • Sponsor: University of North Carolina, Chapel Hill • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug shows promise for ulcerative colitis sufferers
Disease control CompletedThis phase 2b study is designed to have all subjects go into a 12 week induction period to compare different doses of study drug against placebo. After induction is complete all subjects will receive active therapy for 40 weeks, followed by a 12 week follow up period.
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug combo aims to unleash immune system on liver cancer
Disease control OngoingTSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) may stop the growth of tumor cells by allowing the immune system to attack the cancer. This phase II trial is studying how well TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (do…
Phase 2 • Sponsor: University of Hawaii • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug combo aims to keep advanced breast cancer in check
Disease control CompletedThe purpose of this study is to compare the efficacy of olaparib (MK-7339) plus pembrolizumab (MK-3475) with chemotherapy plus pembrolizumab after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC). The primary hypotheses are: 1. Ol…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for lung cancer: drug cocktail trial launches
Disease control Recruiting nowThe purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naïve participants with advanced squamous or…
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New device aims to tame immune attack after stem cell transplants
Disease control Recruiting nowPatients in need of an allogeneic hematopoietic cell transplant (HCT) are at risk of developing graft-versus-host-disease (GVHD). In certain clinical situations, the optimal approach to minimize the risk of GVHD is to perform ex vivo alpha-beta T-cell depletion of the donor cells…
Sponsor: Christopher Dvorak • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New triple therapy shows promise in stomach cancer fight
Disease control OngoingThe study is being conducted to evaluate the efficacy, safety and tolerability of chemotherapy and apatinib with or without camrelizumab in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal ju…
Phase 2/3 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Could 15-Minute workouts recharge aging muscle cells?
Knowledge-focused CompletedThe goal of this interventional study is to learn about the role of mitochondrial function in healthy aging, and then go on and assess the role of a home-based exercise program on the changes seen. The main question\[s\] it aims to answer are: * What alterations in skeletal musc…
Sponsor: University of Nottingham • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingTo evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.
Phase 1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New Triple-Drug cocktail targets tough leukemia mutations
Disease control Recruiting nowThis phase I/II trial studies the side effects and best dose of gilteritinib and to see how well it works in combination with azacitidine and venetoclax in treating patients with FLT3-mutation positive acute myeloid leukemia, chronic myelomonocytic leukemia, or high-risk myelodys…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Chemo-Free hope for lymphoma patients: new combo shows promise
Disease control OngoingFor marginal zone lymphoma (MZL) Rituximab in combination with conventional chemotherapy is widely used for those patients who fail local therapy or do not qualify for such. Depending on the MZL subtype Rituximab/chemotherapy is able to induce in part long remissions, but do not …
Phase 2 • Sponsor: Christian Buske • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Food as medicine? trial tests vouchers and stock boxes against diabetes
Disease control OngoingThe objective of this protocol is to answer the questions: 1) Within food supplementation options, are mailed stock boxes superior to food vouchers in terms of achieving glycemic control? 2) Is the combination of mailed stock boxes and food vouchers superior to either food supple…
Sponsor: State University of New York at Buffalo • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Personalized vaccine shows promise in pancreatic cancer trial
Disease control OngoingThe purpose of this study is to evaluate the safety or treating pancreatic cancer with surgery to remove cancerour tissue, followed by atezolizumab, followed by a personalized cancer vaccine (PCV), and then with chemotherapy.
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug combos tested to improve lymphoma control in younger patients
Disease control OngoingThis phase II trial compares three chemotherapy regimens consisting of bendamustine, rituximab, high dose cytarabine, and acalabrutinib and studies how well they work in treating patients with newly diagnosed mantle cell lymphoma. Drugs used in chemotherapy, such as bendamustine …
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New personalized vaccine aims to keep head and neck cancer from returning
Disease control OngoingThis is a multicenter, open-label, two arms, randomized, phase I/II study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with squamous cell carcinoma of the head and neck (SCCHN).
Phase 1/2 • Sponsor: Transgene • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Heart pump before angioplasty may limit attack damage
Disease control OngoingThe purpose of this research study is to evaluate whether using the the IMPELLA® CP System temporary circulatory assist device for 30 minutes prior to a catheterization procedure has the potential to reduce the damage to the heart caused by a heart attack, compared to the current…
Sponsor: Abiomed Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC